This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic ("wet bench"), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.

Public Health Relevance

While great strides have been made in the diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patient is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA136432-06A1
Application #
8794154
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2009-07-13
Project End
2019-08-31
Budget Start
2014-09-22
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
$460,170
Indirect Cost
$39,369
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Mar, Brenton G; Bullinger, Lars B; McLean, Kathleen M et al. (2014) Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 5:3469
Wang, Leo D; Wagers, Amy J (2011) Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol 12:643-55